Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review

Health Technology Assessment

Volumn 8, Issue 12, 2004, Pages

  Pandor, A ^a   Eastham, J ^b   Beverly, C ^a   Chilcott, J ^a   Paisley, S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; ORNITHINE CARBAMOYLTRANSFERASE;

ANALYTIC METHOD; BIBLIOGRAPHIC DATABASE; CITRULLINEMIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; ECONOMIC ASPECT; ENZYME DEFICIENCY; HEALTH CARE COST; HEALTH PROGRAM; HEALTH SERVICE; HOMOCYSTINURIA; HUMAN; HYPERORNITHINEMIA; INBORN ERROR OF METABOLISM; INFORMATION PROCESSING; MAPLE SYRUP URINE DISEASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; METABOLIC DISORDER; NEWBORN; NEWBORN SCREENING; PHENYLKETONURIA; REVIEW; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; TYROSINEMIA; UNITED KINGDOM;

EID: 17344383506     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8120     Document Type: Review

References (114)

1. Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1(7).
2. Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1(11).
3. National Screening Committee. First report of the National Screening Committee. London: NSC; 1998. (http://www.doh.gov.uk/nsc/library/lib_ind.htm).
4. Wilcken B, Wiley V. Tandem mass spectrometry in the New South Wales newborn screening program. MMWR Morb Mortal Wkly Rep 2001;50 (RR-3): 33.
5. Wilcken B, Wiley V, Carpenter K. Two years of routine newborn screening by tandem mass spectrometry (MSMS) in New South Wales, Australia. J Inherit Metab Dis 2000;23 (Suppl 1):4.
6. Centers for Disease Control and Prevention. Using tandem mass spectrometry for metabolic disease screening among newborns: a report of a work group. MMWR Morb Mortal Wkly Rep 2001;50 (RR-3):1-36.
7. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001;47:1945-55.
8. Muenzer J, Frazier DM, McCandless SE. Incidence and follow-up evaluation of metabolic disorders detected by newborn screening in North Carolina using tandem mass spectrometry. MMWR Morb and Mortal Wkly Rep 2001;50 (RR-3): 28-9.
9. Hoffman G, Litsheim T, Laessig R. Implementation of tandem mass spectrometry in Wisconsin's newborn screening program. MMWR Morb Mortal Wkly Rep 2001;50 (RR-3): 26-7.
10. Ades AE, Walker J, Jones R, Smith I. Coverage of neonatal screening: failure of coverage or failure of information system. Arch Dis Child 2001; 84:476-9.
11. Office for National Statistics. Key population and vital statistics (KPVS): local and health authority areas - population and vital statistics by area of usual residence in the United Kingdom, 1999. Series VS No. 26. London: The Stationery Office; 2001.
12. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd ed. CRD Report No. 4. York: York Publishing Services; 2001.
13. Greenhalgh T, Donald A. Evidence based health care workbook: understanding research: for individual and group learning. London: BMJ Publishing; 2000.
14. Jaeschke R, Guyatt GH, Sackett DL. Evidence-Based Medicine Working Group. Users' guides to medical literature. II: How to use an article about a diagnostic test. A: Are the results of the study valid? JAMA 1994;271:389-91.
15. Jaeschke R, Guyatt GH, Sackett DL. Evidence-Based Medicine Working Group. Users' guides to medical literature. III: How to use an article about a diagnostic test. B: What are the results and will they help me in caring for my patients? JAMA 1994;271:703-7.
16. Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. Acta Paediatrica 1999;88 (Suppl):48-51.
17. Rashed MS, Rahbeeni Z, Ozand PT. Application of electrospray tandem mass spectrometry to neonatal screening. Semin Perinatol 1999;23:183-93.
18. Roscher A, Liebl B, Fingerhut R, Olgemoller B. Prospective study of MS-MS newborn screening in Bavaria, Germany. Interim results. J Inherit Metab Dis 2000;23(Suppl 1):4.
19. Lin WD, Wu JY, Lai CC, Tsai FJ, Tsai CH, Lin SP, Niu DM. A pilot study of neonatal screening by electrospray ionization tandem mass spectrometry in Taiwan. Acta Paediatr Taiwan 2001;42:224-30.
20. Carpenter K, Wiley V, Sim KG, Heath D, Wilcken B. Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275 000 babies. Arch Dis Child Fetal Neonatal Ed 2001;85:F105-9.
21. Pourfarzam M, Morris AA, Appleton M, Craft A, Bartlett K. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 2001; 358:1063-4.
22. Chace DH, Hillman SL, Vanhove JLK, Naylor EW, Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106-13.
23. Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ ftom those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68:1408-18.
24. Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC. Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. Clin Chem 1998; 44:2405-9.
25. Rashed MS, Bucknall MP, Little D, Awad A, Jacob M, Alamoudi M, et al. Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles. Clin Chem 1997;43: 1129-41.
26. Schulze A, Lindner M, Olgemoller K, Mayatepek E, Hoffmann GF. Outcome study of extended neonatal screening for inborn errors of metabolism by electrospray ionization tandem mass spectrometry. 5th Meeting of the International Society for Neonatal Screening, Genova, Italy, 26-29 June 2002.
27. Wiley V, Hammond J, Carpenter K, Wilcken B. Establishing performance indicators for the use of tandem mass spectrometry in a newborn screening programme. 5th Meeting of the International Society for Neonatal Screening, Genova, Italy, 26-29 June 2002.
28. Clayton PT, Doig M, Ghafari S, Meaney C, Taylor C, Leonard JV, et al. Screening for medium chain acyl-CoA dehydrogenase deficiency using electrospray ionisation tandem mass spectrometry. Arch Dis Child 1998;79:109-15.
29. Chace DH, Naylor EW. Expansion of newborn screening programs using automated tandem mass spectrometry. Ment Retard Dev Disab Res Rev 1999; 5:150-4.
30. Hutchesson AC, Bundey S, Preece MA, Hall SK, Green A. A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK. J Med Genet 1998;35:366-70.
31. Poustie VJ, Rutherford P. Dietary interventions for phenylketonuria. The Cochrane library (Issue 1). Oxford: Update Software; 2002.
32. Poustie VJ, Rutherford P. Tyrosine supplementation for phenylketonuria. The Cochrane Library (Issue 1). Oxford: Update Software; 2002.
33. Agostoni C, Riva E, Biasucci G, Luotti D, Bruzzese MG, Marangoni F, Giovannini M. The effects of n-3 and n-6 polyunsaturated fatty acids on plasma lipids and fatty acids of treated phenylketonuric children. Prostaglandins Leukot Essent Fatty Acids 1995;53:401-4.
34. Agostoni C, Scaglioni S, Bonvissuto M, Bruzzese MG, Giovannini M, Riva E. Biochemical effects of supplemented long-chain polyunsaturated fatty acids in hyperphenylalaninemia. Prostaglandins Leukot Essent Fatty Acids 2001;64:111-5.
35. Griffiths P, Paterson L, Harvie A. Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. J Intellect Disabil Res 1995;39:365-72.
36. Robinson M, White FJ, Cleary MA, Wraith E, Lam WK, Walter JH. Increased risk of vitamin B 12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet. J Pediatr 2000; 136:545-7.
37. Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 2000;283:756-62.
38. Cerone R, Schiaffino MC, Di Stefano S, Veneselli E, Phenylketonuria: diet for life or not? Acta Paediatr 1999;88:664-9.
39. Fernandes J, Saudubray JM, van den Berghe G. Inborn metabolic diseases: diagnosis and treatment. Berlin: Springer; 1995.
40. Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, Kelly DA. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999;158 (Suppl 2): S49-54.
41. Schulze A, Frommhold D, Hoffmann GF, Mayatepek E. Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I. Clin Chem 2001; 47:1424-9.
42. Hutchesson AC, Hall SK, Preece MA, Green A. Screening for tyrosinaemia type I. Arch Dis Child Fetal Neonatal Ed 1996;74:F191-4.
43. Laberge C, Grenier A, Valet JP, Morissette J. Fumarylacetoacetase measurement as a mass screening procedure for hereditary tyrosinaemia type I. Am J Hum Genet 1990;47:325-8.
44. Goulden KJ, Moss MA, Cole DE, Tithecott GA, Crocker JF. Pitfalls in the initial diagnosis of tyrosinaemia: three case reports and a review of the literature. Clinical Biochemistry 1987; 20:207-12.
45. Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001.
46. Franken DG, Blom HJ, Boers GH, Tangerman A, Thomas CM, Trijbels FJ. Thiamine (vitamin B1) supplementation does not reduce fasting blood homocysteine concentration in most homozygotes for homocystinuria. Biochim Biophys Acta 1996;1317:101-4.
47. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997;20:295-300.
48. Yap S, Naughten E. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis 1998;21:738-47.
49. Yap S, Rushe H, Howard PM, Naughten ER. The intellectual abilities of early treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine β-synthase deficiency. J Inherit Metab Dis 2001;24:437-47.
50. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine β-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001;21:2080-5.
51. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001. pp. 2007-49.
52. Levy HL, Albers S. Genetic screening of newborns. Annu Rev Genomics and Hum Genet 2000;1:139-77.
53. Morris AAM. Neonatal screening for inborn errors of metabolism. Indian Pediatr 2000;37:1303-6.
54. Peterschmitt MJ, Simmons JR, Levy HL. Reduction of false negative results in screening of newborns for homocystinuria. N Engl J Med 1999;341:1572-6.
55. Chace DH, Hillman SL, Millington DS, Kahler SG, Adam BW, Levy HL. Rapid diagnosis of homocystinuria and other hypermethioninemias from newborns' blood spots by tandem mass spectrometry. Clin Chem 1996;42:349-55.
56. Burlina AB, Ogier H, Korall H, Trefz FK. Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol Genet Metab 2001;72:351-5.
57. Maestri NE, Clissold DB, Brusilow SW. Long-term survival of patients with argininosuccinate synthetase deficiency. J Pediatr 1995;127:929-35.
58. Nicolaides P, Leonard J, Surtees R. Neurological outcome of methylmalonic acidaemia. Arch Dis Child 1998;78:508-12.
59. van der Meer SB, Poggi F, Spada M, Bonnefont JP, Ogier H, Hubert P, et al. Clinical outcome and long-term management of 17 patients with propionic acidaemia. Eur J Pediatr 1996; 155:205-10.
60. Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme-A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994;124:409-15.
61. Touma EH, Charpentier C. Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child 1992;67:142-5.
62. Wilcken B, Hammond J, Silink M. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 1994; 70:410-12.
63. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 1999;80:459-62.
64. Heptinstall LE, Till J, Wraith JE, Besley GT. Common MCAD mutation in a healthy parent of two affected siblings. J Inherit Metab Dis 1995; 18:638-9.
65. Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 1998; 79:116-19.
66. Seddon HR, Gray G, Pollitt RJ, Iitia A, Green A. Population screening for the common G985 mutation causing medium-chain acyl-CoA dehydrogenase deficiency with Eu-labeled oligonucleotides and the DELFIA system. Clin Chem 1997;43:436-42.
67. Ziadeh R, Hoffman EP, Finegold DN, Hoop RC, Brackett JC, Strauss AW, Naylor EW. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995;37:675-8.
68. Hoffmann GF, Zschocke J. Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis 1999; 22:381-91.
69. Monavari AA, Naughten ER. Prevention of cerebral palsy in glutaric aciduria type 1 by dietary management. Arch Dis Child 2000;82:67-70.
70. Collins J, Leonard JV. Natural history of glutaric aciduria type 1. Arch Dis Child 2000;83:87.
71. Bjugstad KB, Goodman SI, Freed CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. J Pediatr 2000;137:681-6.
72. Cairns J, Shackley P. Sometime sensitive, seldom specific: a review of the economic of screening. Health Econ 1993;2:43-53.
73. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150-63.
74. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluations of healthcare interventions. Health Technol Assess 1999;3(2).
75. McIntosh E, Donaldson C, Ryan M. Recent advances in the methods of cost-effectiveness analysis in healthcare. Pharmacoeconomics 1999; 15:357-67.
76. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In Gold MR, Russell LB, Seigal JE, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. pp. 247-75.
77. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
78. Green A, Pollitt RJ. Population newborn screening for inherited metabolic disease: current UK perspectives. J Inherit Metab Dis 1999;22:572-9.
79. Briggs AH. Handling uncertainty in economic evaluation. In Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001. pp. 172-214.
80. Claxton K, Neumann PJ, Araki SS, Weinstein MC. Bayesian value of information analysis: an application to a policy model of Alzheimer's disease. Discussion Papers in Economics (2000/39). Department of Economics and Related Studies, University of York; 2000.
81. Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. CHE Discussion Papers, University of York; 2000.
82. Addison GM. MCAD screening: the need for progress. BMJ 2001; Electronic letter published 31 January 2001 (http://bmj.com/cgi/eletters/322/7278/112#12359) in response to Tanner S, Sharrard M, Cleary M, Walter J, Wraith E, Lee P, et al. Screening for medium chain acyl-CoA dehydrogenase deficiency has still not been evaluated. BMJ 2001;322:112.
83. Curran AL, Sharples PM, White C, Knapp M. Time costs of caring for children with severe disabilities compared with caring for children without disabilities. Dev Med Child Neurol 2001; 43:529-33.
84. Andersson HC, Marble M, Shapira E. Long-term outcome in treated combined methylmalonic acidemia and homocystinemia. Genet Med 1999;1:146-50.
85. den Boer ME, Wanders RJ, Morris AA, Ijlst L, Heymans HS, Wijburg FA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 2002;109:99-104.
86. Boles RG, Buck EA, Blitzer MG, Platt MS, Cowan TM., Martin SK, et al. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr 1998;132:924-33.
87. Hoffmann GF, Athanassopoulos S, Burlina AB, Duran M, de Klerk JB, Lehnert W, et al. Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. Neuropediatrics 1996;27:115-23.
88. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomized control trials. Med Care 1992;30:231-43.
89. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the British Medical Journal. BMJ 1996;313:275-83.
90. Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, et al. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health 1999;53:179-86.
91. Wood JC, Magera MJ, Rinaldo P, Seashore MR, Strauss AW, Friedman A. Diagnosis of very long chain acyl-dehydrogenase deficiency from an infant's newborn screening card. Pediatrics 2001;108:E19.
92. Tanner S, Sharrard M, Cleary M, Walter J, Wraith E, Lee P, et al. Screening for medium chain acyl-CoA dehydrogenase deficiency has still not been evaluated. BMJ 2001;322:112.
93. Netton A, Rees T, Harrison G. Unit costs of health and social care: 2001. Personal Social Services Research Unit, University of Kent at Canterbury; 2002.
94. Department of Health. Reference costs 2001. Leeds: NHS Executive; 2002.
95. Beecham J, O'Neill T, Goodman R. Supporting young adults with hemiplegia: services and costs. Health Soc Care Community 2001;9:51-9.
96. Hutton JL, Colver AF, Mackie PC. Effects of severity of disability on survival in north east England cerebral palsy cohort. Arch Dis Child 2000; 83:468-74.
97. Hutton JL, Pharoah POD. Effects of cognitive, motor and sensory disabilities on survival in cerebral palsy. Arch Dis Child 2002;86:84-90.
98. Singer RB, Strauss D, Shavelle R. Comparative mortality in cerebral palsy patients in California 1980-1996. J Insur Med 1998;30:240-6.
99. Jancar J. Increased life expectancy in people with untreated phenylketonuria. J Intellect Disab Res 1998;42:97-9.
100. Strauss D, Shavelle R. Life expectancy in adults with cerebral palsy. Dev Med Child Neurol 1998; 40:369-75.
101. NHS Executive. Modernisation of pathology services. Health Service Circular (HSC 1999/170). London: Department of Health; 1999.
102. American Academy of Pediatrics. Newborn screening fact sheets (RE9632). Pediatrics 1996; 98:473-501.
103. Dezateux C. Evaluating newborn screening programmes based on dried blood spots: future challenges. Br Med Bull 1998;54:877-90.
104. Pollitt RJ. Tandem mass spectrometry screening: proving effectiveness. Acta Paediatr 1999; 88 (Suppl 432):40-4.
105. Green A. Neonatal screening: current trends and quality control in the United Kingdom. Rinsho Byori 1998;46:211-16.
106. Ades AE, Walker J, Jones R, Thompson S, Leonard JV, Smith I. Obstacles to timely neonatal screening in North Thames. J Med Screen 1998; 5:183-6.
107. Leonard JV, Dezateux C. Screening for inherited metabolic diseases in newborn infants using tandem mass spectrometry. BMJ 2002;324:4-5.
108. Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 2000;154:714-18.
109. Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl-CoA dehydrogenase deficiency: human genome epidemiology review. Genet Med 1999;1:332-9.
110. Clarke JTR, Gates RD, Hogan SE, Barrett M, MacDonald GW. Neuropsychological studies on adolescents with phenylketonuria returned to phenylalanine-restricted diets. Am J Ment Retard 1987;92(3):255-62.
111. Griffiths P, Smith C, Harvie A. Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria. Am J Ment Retard 1997;102(1):27-36.
112. Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. J Inherit Metab Dis 1998;21(1):29-38.
113. Holtzman NA, Welcher DW, Mellits ED. Termination of restricted diet in children with phenylketonuria: a randomised controlled study. N Engl J Med 1975;293(22):1121-4.
114. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1-31.